Clinical Trial: Prevention for the Development of Liver Tumorigenesis by the Oral Supplementation of Branched-chain Amino Acids

Study Status: Completed
Recruit Status: Completed
Study Type: Interventional

Official Title: The Evaluation About the Prevention for the Development of Liver Tumorigenesis by the Oral Supplementation of Branched-chain Amino Acids

Brief Summary: The long-term outcomes of branched-chain amino acid (BCAA) administration in patients undergoing hepatic resection remain unclear. The aim of this study is to assess the impact of oral supplementation with BCAA on the prevention for the development of liver tumorigenesis in patients undergoing liver resection.

Detailed Summary: This study might demonstrate a tendency of the improvement in the cumulative tumor recurrence rate after hepatectomy for liver neoplasm in the Livact group compared to that in the Control Group. The investigators believe that BCAA seems to be a remarkable benefit for liver resection, especially on its reduction in the recurrence of liver cancer. This treatment regimen has potential to offer benefits for clinical use selectively, especially for patients with chronic liver diseases.
Sponsor: Kochi University

Current Primary Outcome: Postoperative tumor recurrence rate [ Time Frame: 5 years follow up ]

Original Primary Outcome: Same as current

Current Secondary Outcome: nutritional status [ Time Frame: 5 years follow up ]

The secondary endpoint was a comparison of measurements of body weight, arm muscle circumference (AMC) between patient groups.


Original Secondary Outcome: Same as current

Information By: Kochi University

Dates:
Date Received: September 13, 2011
Date Started: April 2007
Date Completion:
Last Updated: September 14, 2011
Last Verified: September 2011